Episode Details

#Ozempic #Mounjaro #GLP1 #WeightLoss #ObesityMedicine

Ozempic and Mounjaro can be powerful weight-loss tools — but they can also affect your body in ways many people aren't told before starting. In this video, I break down the real risks, the paradox in the trial data, and what to actually watch for.

In this video I walk through why people with type 2 diabetes tend to lose less weight on these medications than people without it, why a meaningful share of the weight lost on GLP-1s can be muscle rather than fat, what the data actually shows about gastroparesis and other GI complications, what happens metabolically when you stop the medication, how bariatric surgery compares, and exactly what to do to protect your muscle and your health if you're on one of these drugs.

Timestamps:
00:00 The risks nobody tells you about
01:12 Who I am, and why this topic keeps me up at night
03:04 The paradox no one is talking about
04:56 Why your brain needs data from your gut
07:01 The detail your prescriber probably never mentioned
09:26 The lesson every doctor should remember
11:21 A quick word before we go further
12:14 The muscle you didn't know you were losing
17:03 When the stomach stops working
20:16 What happens when you stop
21:03 Why bariatric surgery tells a different story
24:11 What to actually do about it
26:30 The bottom line
27:36 Where to go from here

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

👍 Like
💬 Comment
📌 Share
🔔 Subscribe for more honest conversations about obesity, metabolism, hormones, and real-world health solutions

Bohórquez DV, et al. Gut sensor cells & the vagus nerve. Science, 2018. https://doi.org/10.1126/science.aat5236
Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007. https://doi.org/10.1152/physrev.00034.2006
Semaglutide weight loss with vs. without type 2 diabetes — meta-analysis. Pharmaceuticals (Basel), 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12300051/
ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM, 2008. https://www.nejm.org/doi/full/10.1056/NEJMoa0802743
Gamble JM, et al. Insulin dosage and mortality — confounding example. Lancet Diabetes & Endocrinology, 2017. https://doi.org/10.1016/S2213-8587(16)30316-3
Look M, et al. Body composition changes with tirzepatide (SURMOUNT-1). Diabetes, Obesity and Metabolism, 2025. https://doi.org/10.1111/dom.16275
Wilding JPH, et al. Body composition analysis (STEP 1 study). Conference abstract. https://www.newswise.com/pdf_docs/16159288255831_Wilding%20Abstract.pdf
Wilding JPH, et al. Weight regain after stopping semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
Sodhi M, et al. GI adverse events with GLP-1 receptor agonists. JAMA, 2023. https://pubmed.ncbi.nlm.nih.gov/37796527/
FDA. Wegovy (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/2152